ВЕЗИКАР (СОЛИФЕНАЦИН) В ЛЕЧЕНИИ ГИПЕРАКТИВНОГО МОЧЕВОГО ПУЗЫРЯ
- Авторы: Пушкарь ДЮ1, Колонтарев КБ1, Pushkar DY.2, Kolontarev KB2
-
Учреждения:
- Кафедра урологии МГМСУ, Москва
- Выпуск: № 9 (2009)
- Страницы: 24-31
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/277045
- ID: 277045
Цитировать
Полный текст
Аннотация
Гиперактивный мочевой пузырь (ГАМП) является повсеместно распространенным хроническим заболеванием. На фармацевтическом рынке существует достаточное количество антимускариновых средств, как неселективных (оксибутинин, толтеродин, троспия хлорид, пропиверин), так и селективных (солифенацин, дарифенацин), используемых для лечения ГАМП. Представлены результаты многочисленных рандомизированных многоцентровых исследований по оценке эффективности и безопасности солифенацина (Везикар). Установлено, что прием этого препарата достоверно снижает выраженность проявлений ГАМП и ведет к улучшению качества жизни пациентов. Неоспоримым преимуществом солифенацина являются возможность варьирования доз в зависимости от тяжести симптомов, а также простота применения (1 раз в сутки). Обладая минимальным числом побочных эффектов, солифенацин (Везикар) может быть рекомендован в качестве золотого стандарта в лечении ГАМП у всех групп пациентов.
Ключевые слова
Об авторах
Д Ю Пушкарь
Кафедра урологии МГМСУ, МоскваКафедра урологии МГМСУ, Москва
К Б Колонтарев
Кафедра урологии МГМСУ, МоскваКафедра урологии МГМСУ, Москва
D Yu Pushkar
K B Kolontarev
Список литературы
- Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-66.
- Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36.
- Abrams P, Wein AJ. The overactive bladder: from basic science to clinical management. Urology 1997;50(Suppl. 6A):1-144.
- Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 2002;21:167-78.
- Cardozo L, Robinson D. Special considerations in premenopausal and postmenopausal women with symptoms of overactive bladder. Urology 2002;60(Suppl. 5A):64−71.
- Ouslander JG. Geriatric considerations in the diagnosis and management of overactive bladder. Urology 2002;60(Suppl. 5A):50−55.
- Yap P, Tan D. Urinary incontinence in dementia. A practical approach. Aus Fam Physician 2006;35:237−41.
- Djavan B. Lower urinary tract symptoms/benign prostatic hyperplasia: fast control of the patient's quality of life. Urology 2003;62(3 Suppl. 1):6−14.
- Abrams P, Artbani W, Gajewski JB, Hussain I. Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology 2006;68(Suppl. 2A):17−28.
- International Continence Society. Management recommendations. In: Abrams P, Cardozo L, Khoury S, Wein A (eds). 3rd International Consultation on Incontinence, 2005.
- Hampel C, Hohenfellner M, Abrams P, et al. European Association of Urology. Guidelines on incontinence. 1999.
- Wein AJ. Diagnosis and treatment of the overactive bladder. Urology 2003;62(Suppl. 5B):20−27.
- Norton P, Brubaker L. Urinary incontinence in women. Lancet 2006;367:57−67.
- Ostaszkiewicz J, Johnston L, Roe B. Timed voiding for the management of urinary incontinence in adults. Cochrane Database Syst Rev 2004.
- Burgio KL. Influence of behavior modification on overactive bladder. Urology 2002;60(Suppl. 5A):72−77.
- Wallace SA, Roe B, Williams K, et al. Bladder training for urinary incontinence in adults. Cochrane Database Syst Rev 2003; CD001308.
- Salvatore S, Soligo M, Proietti F, et al. Overactive bladder syndrome: considerations in pharmacotherapy and new perspectives. Eur J Obstet Gynecol Reprod Biol 2005;120:129−33.
- Marieb EN. The urinary system. In: Human anatomy & physiology. 5th ed. San Francisco: Benjamin Cummings, 2001.
- Dmochowski RR, Appell RA. Advancements in pharmacologic management of the overactive bladder. Urology 2000;56(Suppl. 6A):41−49.
- Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacology 2006;147:S80−S87.
- Vesicare. Summary of product characteristics, September 2005.
- Ohtake A, Ukai M, Hatanaka T, et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 2004;492:243−50.
- Chapple CR, Arano P, Bosch JLHR, et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 2004;93:71−77.
- Brunton S, Kuritzky L. Recent developments in the management of overactive bladder. Curr Med Res Opin 2005;21:71−80.
- Chu F, Smith N. Efficacy and safety of 10 mg solifenacin succinate, a once-daily antimuscarinic agent, in a randomised, double-blind, placebo-controlled trial in patients with overactive bladder. IN PROGRESS.
- Govier FE, Smith N. A randomised, double-blind, placebo-controlled study to assess the efficacy and safety of 10 mg solifenacin succinate trial in patients with overactive bladder syndrome. IN PROGRESS.
- Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004;93:303−10.
- Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172:1919-24.
- Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended-release tolterodine at treating overactive bladder syndrome: Results of the STAR Trial. Eur Urol 2005;48:464−70.
- Toglia M, Andoh M, Hussain I. Solifenacin improves urgency symptoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder. International Continence Society annual meeting, 2006. Abstract 155.
- Chancellor M, Whitmore K, Snyder J, et al. Solifenacin treatment of overactive bladder in patients previously treated with tolterodine extended release. Obstet Gynecol. Details TBC.
- Garely AD, Kaufman JM, Sand PK, Smith N, Andoh M. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the Vesicare Open-Label Trial (VOLT). Clin Ther 2006;28:1935-46.
- Samuels TA, Mitcheson HD, Vardy MD, et al. Solifenacin significantly improves overactive bladder symptoms, symptom-associated bother and other patient-related outcomes:Results from VIBRANT, a double-blind, placebo-controlled trial. EAU annual meeting, 2009. Abstract 190.
Дополнительные файлы
![](/img/style/loading.gif)